Senseonics Holdings Inc. Common Stock (SENS)
Stock · NASDAQ · Health Care
$7.76as of 10/16/2026
Price chart
Active signals
SENS Signal Track Record
How signals performed across all stocks →What SENS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -6.4% | 39% | September 17, 2026 |
| Bollinger Band BreakdownActive now | 20 | -1.3% | 50% | June 23, 2026 |
| Bollinger Band Breakout | 20 | -9.2% | 45% | August 7, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -20.1% | 17% | June 8, 2026 |
| Any 20-session window (baseline) | -3.6% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SENS
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin se…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 130
- Website
- www.senseonics.com/
Fundamentals
- 1-day range
- $7.96$8.23
- Market cap
- $215.29M
- P/E (trailing)
- —
- P/E (forward)
- -4.09
- EPS (trailing)
- $-2.24
- Dividend yield
- —
- Beta
- 1.02
- Avg. volume
- 685.3K
How Senseonics Holdings Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 2, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Senseonics Holdings Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SENSSenseonics Holdings Inc. Common Stock$7.77▼ 5.59%Market cap $215.29MP/E —$4.79$10.64
- PDEXPro-Dex Inc. Common Stock$58.26▼ 2.93%Market cap $209.06MP/E 14.11$23.47$77
- EMBCEmbecta Corp. Common Stock$6.27▼ 2.79%Market cap $207.65MP/E 4.00$2.77$14.91
- INFUInfuSystems Holdings Inc. Common Stock$13.4▼ 3.74%Market cap $236.42MP/E 31.71$7.29$13.85
- LUCDLucid Diagnostics Inc. Common Stock$0.478▼ 8.08%Market cap $193.54MP/E —$0.5$1.63
- APYXApyx Medical Corporation Common Stock$2.55▼ 0.39%Market cap $174.35MP/E —$2.32$5.08
- KRMDKORU Medical Systems Inc. Common Stock (DE)$3▼ 0.99%Market cap $163.52MP/E —$2.86$6.61
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SENS Senseonics Holdings Inc. Common Stock | $215.29M | — | $7.77 | ▼ 5.59% | $4.79$10.64 |
| PDEX Pro-Dex Inc. Common Stock | $209.06M | 14.11 | $58.26 | ▼ 2.93% | $23.47$77 |
| EMBC Embecta Corp. Common Stock | $207.65M | 4.00 | $6.27 | ▼ 2.79% | $2.77$14.91 |
| INFU InfuSystems Holdings Inc. Common Stock | $236.42M | 31.71 | $13.4 | ▼ 3.74% | $7.29$13.85 |
| LUCD Lucid Diagnostics Inc. Common Stock | $193.54M | — | $0.478 | ▼ 8.08% | $0.5$1.63 |
| APYX Apyx Medical Corporation Common Stock | $174.35M | — | $2.55 | ▼ 0.39% | $2.32$5.08 |
| KRMD KORU Medical Systems Inc. Common Stock (DE) | $163.52M | — | $3 | ▼ 0.99% | $2.86$6.61 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Senseonics Holdings Q2 2026 Earnings Call: Complete Transcriptbenzinga · 10/12/2026
- Beta Bionics Stock Down Despite iLet-Eversense 365 Integration DealYahoo · 9/29/2026
- Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic PancreasYahoo · 9/14/2026
- Senseonics Partners With Beta Bionics To Integrate Its Eversense 365 CGM With Beta Bionics’ iLet Bionic Pancreas Automated Insulin Delivery SystemBenzinga · 9/14/2026
Insider Activity
Insider Actions →- Douglas A. Roeder · August 19, 2026 · Buy14.0K @ $8.98
- Edelman Steven · July 1, 2026 · Grant2.4K @ $5.36
- Douglas S. Prince · July 1, 2026 · Grant1.5K @ $5.36
- Edward Fiorentino · July 1, 2026 · Grant2.6K @ $5.36
- Douglas A. Roeder · July 1, 2026 · Grant2.8K @ $5.36
- Frederick T. Sullivan · June 15, 2026 · Tax Withholding5.4K @ $7.18
- Francine Kaufman · June 15, 2026 · Tax Withholding4.0K @ $7.18
- Mukul JAIN · June 15, 2026 · Tax Withholding16.2K @ $7.18
- Timothy T. Goodnow · June 15, 2026 · Tax Withholding32.6K @ $7.18
- Kenneth L. Horton · June 15, 2026 · Tax Withholding9.5K @ $7.18
- Brian B. Hansen · June 15, 2026 · Tax Withholding5.4K @ $7.18
- Sharon Larkin · May 20, 2026 · Grant13.6K
- Sharon Larkin · May 20, 2026 · Grant9.9K
- Edelman Steven · May 20, 2026 · Grant13.6K
- Edelman Steven · May 20, 2026 · Grant9.9K
Institutional Ownership
March 31, 2026
- Total shares held
- 8.93M
- Total value held
- $59.32M
- Institutional holders
- 83
- Unknown1.77M
- Unknown1.62M
- Unknown568.7K
- Unknown560.4K
- Unknown525.5K
- Unknown500.0K
- Unknown466.5K
- Unknown464.4K
- Unknown448.2K
- Unknown221.2K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Beta Bionics and Senseonics announce iLet-Eversense 365 integration
Beta Bionics and Senseonics announced a deal to integrate the iLet automated insulin delivery system with the Eversense 365 continuous glucose monitor. This partnership aims to provide a more seamless solution for patients managing diabetes. The news highlights a strategic move to combine two major technologies in the diabetes care market.
Beta Bionics and Senseonics announce iLet-Eversense 365 integration. Beta Bionics and Senseonics announced a deal to integrate the iLet automated insulin delivery system with the Eversense 365 continuous glucose monitor. This partnership aims to provide a more seamless solution for patients managing diabetes. The news highlights a strategic move to combine two major technologies in the diabetes care market.